微生态制剂在老年人肠道菌群失衡中的应用

人类从青年到老年这个过程,随着年龄的增长,退行性和感染性疾病的易感性也增加,其可能与人体肠道菌群失衡有着密切的关系。人体肠道内生理菌群对机体健康具有重要的作用,其变化与宿主的免疫功能、食物、疾病和年龄等有关。了解老年人肠道菌群特点,且在老年人肠道菌群失调相关疾病中合理介入微生态制剂,将大大有利于老年人身体健康。本文就老年人肠道菌群失衡相关疾病以及微生态制剂在这些疾病中的应用进行综述。     

中医药治疗菌群失调腹泻的研究进展

肠道菌群与人体存在共生关系，并易受外部环境及肠道内环境的调节。当外部环境或肠道条件发生改变时，可能引起肠道菌群在种类、丰度、比例、定位和生物学特性上的变化，即发生肠道菌群失调。以抗生素相关性腹泻为代表的菌群失调腹泻的发病率逐年上升。中医药治疗菌群失调腹泻的优势不断显现，表现在症状缓解显著、治愈率高和复发率低，这与中医药纠正肠道内、外环境，调整肠道菌群，提高肠道免疫力有关。本文论述了菌群失调腹泻的肠道菌群改变特征、中医药治疗菌群失调腹泻的临床疗效及机制，为临床应用及实验研究提供理论依据。     

肠道菌群改变与结核分枝杆菌感染相互作用的研究进展

人体内肠道菌群数量庞大,参与机体物质代谢以及免疫应答反应,成为目前众多研究的热点。肠道菌群对于维持呼吸系统稳态,特别是肺部的稳态发挥着重要作用。目前越来越多的结果证明肠道菌群对机体免疫系统具有诱导和调节作用,这种免疫反应的改变对于结核病的发病和治疗有着深远意义。本文梳理了近年来国内外发表的肠道菌群与结核病相关的文献,讨论了结核分枝杆菌感染后肠道菌群的变化特征,分析肠道菌群对机体免疫应答的影响机制,探讨了饮食结构以及微生态制剂在结核病治疗过程中起到的作用,以期为有效预防和治疗结核病提供理论基础。     

肠道菌群与肝癌的研究进展

微生态是微生物与机体在长期进化和相互作用过程中形成的特殊生态系统,对机体健康与疾病起着重要作用。肠道菌群作为人体微生态的重要组成部分,通过营养代谢、免疫调节和基因调控参与人体内一系列重要的生理和病理过程。肠道菌群失调可导致胆汁酸代谢异常、内毒素释放、肠道稳态破坏、模式识别受体激活等,这些都可直接或间接促进肝癌的发展。本文从以上因素着手,通过文献检索对肠道菌群与肝癌发生发展关系的研究作一简要综述。     

肠道菌群参与宿主免疫应答的作用及机制研究进展

肠道菌群作为动物体内重要的组成部分,能够直接参与机体的免疫调控作用,促进机体免疫系统发育,维持正常免疫功能。同时,免疫系统对肠道菌群又有调控和制约作用。本文主要综述了肠道菌群的组成以及影响肠道菌群变化的因素,系统阐述了肠道菌群与疾病相互作用的机制,总结了肠道菌群在宿主感染与免疫应答中的作用,为开展肠道菌群参与机体免疫应答的机制方面的研究提供新的思路。     

肠道菌群调节与缺血性脑卒中的中西医治疗研究进展CSCD

肠道菌群与大脑之间通过肠道菌群-肠-脑轴进行双向调节。研究表明,肠道菌群与缺血性脑卒中(ischemic stroke,IS)密切相关,肠道菌群失调通过影响血压、动脉粥样硬化、免疫、神经内分泌和炎症等途径干预IS的发生发展。IS发生后的自主神经功能紊乱和应激反应等又会导致肠道菌群失调,进一步加重脑损伤。因此,肠道菌群可能是临床预防和治疗IS的一个潜在靶点。本文综述了基于肠道菌群调节的中西医结合治疗IS的研究进展,对益生菌、粪菌移植、抗生素及中药在调节肠道菌群,改善IS脑损伤的作用及潜在机制方面进行深入探讨,以期为IS的药物干预研究提供新的视角。     

应用PCR-DGGE法评价石斛多糖对肠道微生态失调的调节作用

目的 从微生态学角度研究石斛多糖治疗肠道微生态失调小鼠的作用及初步机制.方法 盐酸林可霉素灌胃制备肠道菌群失调小鼠模型,应用石斛多糖进行治疗,同时设正常对照组、丽珠肠乐组、阴性对照组,给药7d后处死小鼠,应用PCR-DGGE法检测肠道菌群丰富度、血清IL-2.结果 应用盐酸林可霉素灌胃3d后,小鼠肠道菌群丰富度、血清IL-2降低,持续治疗7d后,石斛多糖治疗小鼠肠道菌群丰富度、血清IL-2增高.结论 石斛多糖具有扶植肠道正常菌群生长,调整菌群失调,提高机体免疫力的作用.     

肠道菌群与结核病之间相关性的研究进展

随着新一代测序技术的发展,肠道菌群成为生物学研究领域的一大热点,特别是肠道菌群与人体各种疾病之间的关系受到广泛关注。目前已有研究发现结核分枝杆菌感染会引起肠道菌群改变,而肠道菌群失调也会增加机体对结核分枝杆菌的易感性,两者通过机体免疫反应、菌群代谢产物等因素相互影响。本文就肠道菌群与结核病的关系、肠道菌群与结核病相互影响的可能机制、抗结核治疗对肠道菌群的影响等方面的相关研究进行综述。     

肠道菌群在2型糖尿病合并骨质疏松中的作用探析

骨质疏松是一种隐匿性骨密度降低的全身骨代谢性疾病,具有较高的致残率及致死率,严重影响患者生活质量。而骨质疏松作为糖尿病在骨骼系统中的常见并发症,在临床治疗中却忽略了二者之间存在的内在联系,采用分开诊治的方案。大量研究表明,肠道菌群与多种代谢性疾病相关,而2型糖尿病患者体内存在着明显的肠道菌群失调。因此考虑肠道菌群失调可能影响糖尿病合并骨质疏松的发生发展。本文通过深入阐明三者之间的关系,积极探索肠道菌群在糖尿病及骨质疏松中的作用,发现2型糖尿病患者肠道菌群失调,可导致胰岛素抵抗、炎症反应和胰岛素样生长因子-1缺少,进一步影响骨代谢过程,进而提出调节肠道菌群是治疗2型糖尿病合并骨质疏松的新方向。     

肠道菌群在2型糖尿病并发抑郁症中的作用探析

抑郁症作为2型糖尿病常见并发症,不仅严重危害人体的健康,而且增加了疾病的治疗难度。临床中对于本病的治疗通常将二者分开,采用降糖与抗抑郁联合的方法,却忽视了抑郁症作为2型糖尿病的并发症,两者必定存在内在联系。研究表明,2型糖尿病患者肠道菌群存在明显失衡,而肠道菌群与抑郁症的发生密切相关,因此肠道菌群可能在2型糖尿病并发抑郁症中起着重要作用,本文通过论述三者的关系,认为肠道菌群失调可能是糖尿病并发抑郁症的关键因素,提出肠道菌群可能是干预2型糖尿病并发抑郁的新靶点,以期为2型糖尿病并发抑郁症的治疗提供新的途径。     

MicroRNAs与帕金森病关系的研究进展

帕金森病(Parkion's disease,PD)作为一种复杂的神经系统退行性疾病,已经成为严重影响中老年人健康及生活质量的重要疾病之一。病理变化为中枢神经系统黑质及纹状体通路的多巴胺(Dopamine,DA)能神经元发生退行性变性以及纹状体DA含量的减少,导致纹状体内DA和乙酰胆碱平衡失调而发病。其发病机制尚不明确,但普遍认为可能是遗传易感性、环境毒素几种因素共同作用的结果,而导致黑质DA能神经元变性凋亡则与氧化应激、蛋白酶体功能异常、自我吞噬、蛋白质合成减少、转录信号改变等因素关系密切。近年来,人们从各个相关领域对其进行深入研究,其发病机制正逐步被人们所破解。小NRA(miRNA,mircoRNA)是一类非编码miRNA,通过与mRNA靶基因互补配对调控转录后水平的基因表达。miRNA对神经元细胞中的信号调控具有重要作用,目前关于miRNA与PD之间的关系越来越受到重视。本综述通过对miRNA与PD关系的探讨,为研究PD的致病机制提供新的线索,从而为PD患者治疗提供一个新的视角。     

Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease

The presence of α-synuclein aggregates in the characteristic Lewy body pathology seen in idiopathic Parkinson''s disease (PD), together with α-synuclein gene mutations in familial PD, places α-synuclein at the center of PD pathogenesis. Decreased levels of the chaperone-mediated autophagy (CMA) proteins LAMP-2A and hsc70 in PD brain samples suggests compromised α-synuclein degradation by CMA may underpin the Lewy body pathology. Decreased CMA protein levels were not secondary to the various pathological changes associated with PD, including mitochondrial respiratory chain dysfunction, increased oxidative stress and proteasomal inhibition. However, decreased hsc70 and LAMP-2A protein levels in PD brains were associated with decreases in their respective mRNA levels. MicroRNA (miRNA) deregulation has been reported in PD brains and we have identified eight miRNAs predicted to regulate LAMP-2A or hsc70 expression that were reported to be increased in PD. Using a luciferase reporter assay in SH-SY5Y cells, four and three of these miRNAs significantly decreased luciferase activity expressed upstream of the lamp-2a and hsc70 3′UTR sequences respectively. We confirmed that transfection of these miRNAs also decreased endogenous LAMP-2A and hsc70 protein levels respectively and resulted in significant α-synuclein accumulation. The analysis of PD brains confirmed that six and two of these miRNAs were significantly increased in substantia nigra compacta and amygdala respectively. These data support the hypothesis that decreased CMA caused by miRNA-induced downregulation of CMA proteins plays an important role in the α-synuclein pathology associated with PD, and opens up a new avenue to investigate PD pathogenesis.     

TET2在帕金森病细胞模型中的表达及机制研究

目的:迄今为止,帕金森病(PD)发生的分子机制尚未完全阐明,本研究旨在体外细胞模型中寻找PD新型表观遗传标志物,探索其发病机制。方法:本次研究使用的细胞为神经母细胞瘤细胞系SH-SY5Y。首先,我们用CCK-8检测细胞活力,选取合适浓度的MPP+构建PD细胞损伤模型。再用PBS和MPP+分别处理SH-SY5Y细胞,用RT-qPCR检测了几个甲基化酶与去甲基化酶DNMT1,DNMT3A,DNMT3B及TET1, TET2, TET3的mRNA的表达水平,并用蛋白印迹检测TET2蛋白水平,免疫荧光检测了TET2蛋白定位。进一步用慢病毒转染SH-SY5Y细胞敲低TET2后,检测细胞增殖。结果:本研究发现,MPP+对SH-SY5Y细胞增殖的抑制具有时间与浓度依赖性,我们最终选择2.5 mM MPP+作为后续的细胞处理浓度。与对照组相比,MPP+处理细胞TET2的mRNA及蛋白水平表达均增加,且蛋白进入细胞核增加;同时发现,敲低TET2表达可以延缓MPP+对SH-SY5Y细胞增殖的抑制作用。结论:在当前的研究中,我们报道了TET2蛋白可能是PD新型的表观遗传学标志物,提示我们将来也许可以使用TET2抑制剂来治疗PD,因此本研究有可能为PD提供新的治疗方向和靶点。     

Altered Ion Channel Formation by the Parkinson's-Disease-Linked E46K Mutant of α-Synuclein Is Corrected by GM3 but Not by GM1 Gangliosides

α-Synuclein (α-syn) is an amyloidogenic protein that plays a key role in the pathogenesis of Parkinson's disease (PD). The ability of α-syn oligomers to form ionic channels is postulated as a channelopathy mechanism in human brain. Here we identified a ganglioside-binding domain in α-syn (fragment 34-50), which includes the mutation site 46 linked to a familial form of PD (E46K). We show that this fragment is structurally related to the common glycosphingolipid-binding domain (GBD) shared by various microbial and amyloid proteins, including Alzheimer's β-amyloid peptide. α-Syn GBD interacts with several glycosphingolipids but has a marked preference for GM3, a minor brain ganglioside whose expression increases with aging. The α-syn mutant E46K has a stronger affinity for GM3 than the wild-type protein, and the interaction is inhibited by 3′-sialyllactose (the glycone part of GM3). Alanine substitutions of Lys34 and Tyr39 in synthetic GBD peptides resulted in limited interaction with GM3, demonstrating the critical role of these residues in GM3 recognition. When incubated with reconstituted phosphatidylcholine bilayers, the E46K protein formed channels that are five times less conductive than those formed by wild-type α-syn, exhibit a higher selectivity for cations, and present an asymmetrical response to voltage and nonstop single-channel activity. This E46K-associated channelopathy was no longer observed when GM3 was present in phosphatidylcholine bilayers. This corrective effect was highly specific for GM3, since it was not obtained with the major brain ganglioside GM1 but was still detected in bilayer membranes containing both GM3 and GM1. Moreover, synthetic GBD peptides prevented the interaction of α-syn proteins with GM3, thus abolishing the regulatory effects of GM3 on α-syn-mediated channel formation. Overall, these data show that GM3 can specifically regulate α-syn-induced channel formation and raise the intriguing possibility that this minor brain ganglioside could play a key protective role in the pathogenesis of PD.     

Engineering superactive granulocyte macrophage colony‐stimulating factor transferrin fusion proteins as orally‐delivered candidate agents for treating neurodegenerative disease

Intravenously injected granulocyte macrophage colony‐stimulating factor (GM‐CSF) has shown efficacy in Alzheimer's Disease (AD) and Parkinson's Disease (PD) animal studies and is undergoing clinical evaluation. The likely need for dosing of GM‐CSF to patients over months or years motivates pursuit of avenues for delivering GM‐CSF to circulation via oral administration. Flow cytometric screening of 37 yeast‐displayed GM‐CSF saturation mutant libraries revealed residues P12, H15, R23, R24, and K72 as key determinants of GM‐CSF's CD116 and CD131 GM‐CSF receptor (GM‐CSFR) subunit binding affinity. Screening combinatorial GM‐CSF libraries mutated at positions P12, H15, and R23 yielded variants with increased affinities toward both CD116 and CD131. Genetic fusion of GM‐CSF to human transferrin (Trf), a strategy that enables oral delivery of other biopharmaceuticals in animals, yielded bioactive wild type and variant cytokines upon secretion from cultured Human Embryonic Kidney cells. Surface plasmon resonance (SPR) measurements showed that all evaluated variants possess decreases in CD116 and CD131 binding K_D values of up to 2.5‐fold relative to wild type. Improved affinity led to increased in vitro bioactivity; the most bioactive variant, P12D/H15L/R23L, had a leukocyte proliferation assay EC₅₀ value 3.5‐fold lower than the wild type GM‐CSF/Trf fusion. These outcomes are important first steps toward our goal of developing GM‐CSF/Trf fusions as orally available AD and PD therapeutics. © 2015 American Institute of Chemical Engineers Biotechnol. Prog., 31:668–677, 2015     

α‐Synuclein stimulation of monoamine oxidase‐B and legumain protease mediates the pathology of Parkinson's disease

Dopaminergic neurodegeneration in Parkinson's disease (PD) is associated with abnormal dopamine metabolism by MAO‐B (monoamine oxidase‐B) and intracellular α‐Synuclein (α‐Syn) aggregates, called the Lewy body. However, the molecular relationship between α‐Syn and MAO‐B remains unclear. Here, we show that α‐Syn directly binds to MAO‐B and stimulates its enzymatic activity, which triggers AEP (asparagine endopeptidase; legumain) activation and subsequent α‐Syn cleavage at N103, leading to dopaminergic neurodegeneration. Interestingly, the dopamine metabolite, DOPAL, strongly activates AEP, and the N103 fragment of α‐Syn binds and activates MAO‐B. Accordingly, overexpression of AEP in SNCA transgenic mice elicits α‐Syn N103 cleavage and accelerates PD pathogenesis, and inhibition of MAO‐B by Rasagiline diminishes α‐Syn‐mediated PD pathology and motor dysfunction. Moreover, virally mediated expression of α‐Syn N103 induces PD pathogenesis in wild‐type, but not MAO‐B‐null mice. Our findings thus support that AEP‐mediated cleavage of α‐Syn at N103 is required for the association and activation of MAO‐B, mediating PD pathogenesis.     

Neuroprotective effects of extract of Acanthopanax senticosus harms on SH-SY5Y cells overexpressing wild-type or A53T mutant α-synuclein

Extract of Acanthopanax senticosus harms (EAS) has been shown to have neuroprotective effects on dopaminergic neurons in Parkinson's disease (PD) mice model. α-Synuclein is a key player in the pathogenesis of PD, the elevated level of which is deleterious to dopaminergic neurons, and enhancing its clearance might be a promising strategy for treating PD. To assess the potential of EAS in this regard, we investigated its effect on the SH-SY5Y cells overexpressing wild-type α-synuclein (WT-α-Syn) or A53T mutant α-synuclein (A53T-α-Syn), and the implicated pathway it might mediate. After treatment with EAS, the changes of α-synuclein, caspase-3, parkin, phospho-protein kinase B (Akt), phospho-glycogen synthase kinase 3 beta (GSK3β), and phospho-microtubule-associated protein tau (Tau) in WT-α-Syn or A53T-α-Syn transgenic cells were reverted back to near normal levels, demonstrated by the western blotting and quantitative real-time PCR outcomes. The neuroprotective effects of EAS may be able to protect WT-α-Syn or A53T-α-Syn transgenic SH-SY5Y cells from α-synuclein overexpression and toxicity. Therefore, we speculate that EAS might be a promising candidate for prevention or treatment of α-synuclein-related neurodegenerative disorders such as PD.     

Genome-wide data mining to construct a competing endogenous RNA network and reveal the pivotal therapeutic targets of Parkinson's disease

Parkinson's disease (PD) is one of the most common neurodegenerative movement disorders, for which there has been no effective treatments. To clarify the pathogenesis of PD, we constructed a competing endogenous RNA (ceRNA) network based on the genome-wide RNA sequencing data. It was found that 92 RNAs were differentially expressed, including 50 mRNAs, 25 miRNAs and 17 lncRNAs, based on which a ceRNA network was constructed and evaluated from 4 aspects of number of nodes, topological coefficients, closeness centrality and betweenness centrality. The functional annotation and enrichment analysis suggested that 6 functional modules, particularly the peripheral nervous system development and toxin metabolic process, dominated the development of PD. To validate the assumption, the gene set enrichment analysis (GSEA) was conducted basing on the genome-wide RNAs regardless whether they were differentially expressed or not. Consistently, the results revealed that dysregulation of MAG, HOXB3, MYRF and PLP1 led to metabolic disorders of sphingolipid and glutathione, which contributed to the pathogenesis of PD. Also, in-depth mining of previous literature confirmed a pivotal role of these dysregulated RNAs, which had been indicated to be potential diagnostic and therapeutic biomarkers of PD. Overall, we constructed a ceRNA network based on the dysregulated mRNAs, lncRNAs and miRNAs in PD, and the aberrant expression of MAG, HOXB3, MYRF and PLP1 caused metabolism disorder of sphingolipid and glutathione, and these genes are of great significance for the diagnosis and treatment of PD.     

Intranasal LPS-Mediated Parkinson’s Model Challenges the Pathogenesis of Nasal Cavity and Environmental Toxins

Accumulating evidence implicates the relationship between neuroinflammation and pathogenesis in idiopathic Parkinson''s disease (iPD). The nose has recently been considered a gate way to the brain which facilitates entry of environmental neurotoxin into the brain. Our study aims to build a PD model by a natural exposure route. In this report, we establish a new endotoxin-based PD model in mice by unilateral intranasal (i.n.) instillation of the lipopolysaccharides (LPS) every other day for 5 months. These mice display a progressive hypokinesia, selective loss of dopaminergic neurons, and reduction in striatal dopamine (DA) content, as well as α-synuclein aggregation in the SN, without systemic inflammatory and immune responses. This new PD model provides a tool for studying the inflammation-mediated chronic pathogenesis and searching for therapeutic intervention in glia-neuron pathway that will slow or halt neurodegeneration in PD.     

磁共振波谱分析与帕金森病患者Hoehn&Yahr分级的相关性研究

目的:探讨磁共振波谱分析(MRS)与帕金森病(PD)HoehnYahr分级之间的相关性。方法:选择2016年9月-2017年8月我院收治的60例PD患者为研究对象,根据HoehnYahr分级将患者分为早期PD组32例、中期PD组18例、晚期PD组10例,并选择同时期在门诊进行健康体检的20例志愿者作为对照组。对各组研究对象的双侧基底节、双侧额叶、双侧丘脑区进行MRS,并分析PD患者HoehnYahr分级与MRS的关系。结果:晚期PD组双侧基底节、双侧额叶、双侧丘脑区NAA/Cr、NAA/Cho、Cho/Cr比值均低于中期PD组、早期PD组、对照组,且中期PD组低于早期PD组、对照组,早期PD组低于对照组,差异有统计学意义(P0.05)。通过Spearman相关性分析显示,MRS检测出PD患者NAA/Cr、NAA/Cho、Cho/Cr比值与HoehnYahr分级间呈负相关性(P0.05)。结论:MRS与PD患者的HoehnYahr分级具有负相关性,并且可通过MRS预测患者疾病的严重程度,以对其进行相应的治疗以及预后评估。